Holly is an expert in providing bespoke HEOR and access solutions to clients. She has extensive experience in health economics, conducting over 30 systematic literature reviews and 20 cost-effectiveness analyses across multiple disease areas. She has been instrumental in numerous HTAs and represented pharmaceutical companies at committee meetings. Holly also contributes to value dossiers and statistical analyses, particularly in survival analysis. With a rich background in training, guide creation, and technical reports, she helps clients navigate complex healthcare landscapes.
Holly holds a Master's in Economic Evaluation in Healthcare (Distinction) from City University London and a First-Class degree in Engineering Mathematics from the University of Bristol.
Led submissions to NICE, SMC, and AWMSG, with expertise in immune-oncology and survival analysis.
Systematic literature review and economic modelling expertise
Conducted over 30 literature reviews and 20 cost-effectiveness models across various disease areas.
Significant background in statistical analysis
Performed advanced survival analyses, contributing to key dossiers and health economic publications.
Experience in range of therapy areas:
Haematology, thrombosis
Oncology
Infectious diseases
Gastroenterology
Orphan/ultra-orphan conditions
FIECON exceeds my expectations by genuinely trying to achieve the best outcomes for our company. Their flexibility to adapt to unexpected changes and apply technical rigour, while respecting the commercial focus of the company is unparalleled. We see FIECON as part of our extended team.”
Senior Market Access Manager, Mid-sized Pharma
It was brilliantly smart and very well explained. It seems obvious now but that is what genius is, making complex things appear simple.”
Associate Director, Mid-sized Pharma
FIECON are my go to trusted partner. The team deliver high-quality work to timeline, every time. But more than this, FIECON has worked as part of our team, working towards achieving the best possible outcome by providing high level strategic input and challenge during our discussions.”
Market Access Director, Small Biotech
FIECON’s highly skilled expert team helped us to successfully tackle a number of tough pricing and access challenges. Apart from their flawless technical expertise, we have a reliable thought partner to pressure test new ideas and strategies that have a broader relevance than purely health economic aspects.”
Disease Area Director, Big Pharma
The pricing and market access research was a high quality work project, which included detailed information to define the overall and country strategy while the gap analysis was instrumental in the next steps preparation. ”
Executive Director, Biotech
FIECON’s strategic approach to problem solving is a breath of fresh air. We highly value their HTA knowledge and expertise, and they consistently deliver the best solution for us.”
Value Demonstration & Access Lead, Big Pharma
It is a pleasure to work with FIECON. The team are passionate about what they do and it really shows in their high-quality, creative solutions. Working with FIECON gives your projects the highest chance of success.”
Senior Vice President, Small Biotech
FIECON’s team is highly experienced, commercially focused, responsive and flexible. A particular strength I highlight is that FIECON’s team becomes a true partner with all company functions that they interact with. ”
By clicking “Accept All Cookies”, you agree to the storing of cookies on your device to enhance site navigation, analyze site usage and assist in our marketing efforts. More info
By clicking “Accept All Cookies”, you agree to the storing of cookies on your device to enhance site navigation, analyze site usage and assist in our marketing efforts.
